Thyroid hormone ligands and metabolic diseases

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Thyroid hormones, L-3, 5, 3'-triiodo-L-thyronine (T3) and L-3, 5, 3', 5'-tetraiodo-L-thyronine (T4), are crucial for vertebrate metabolism, development, and homeostasis.
• Cardiovascular side effects limit the pharmacological use of endogenous thyroid hormones.
• Two thyroid hormone receptor (TR) subtypes, TRalpha and TRbeta, exist, with TRalpha predominantly in the heart.

Purpose of the Study:

• To review the significant efforts in developing selective TR agonists for potential therapeutic applications.
• To discuss the prospects of TR agonists in treating metabolic diseases.
• To evaluate the current status and future directions of TR ligand development.

Main Methods:

• Review of academic and industrial research over the past decade.
• Analysis of strategies for developing tissue-selective or TRbeta-selective TR agonists.
• Assessment of chemical diversity and clinical progression of TR ligands.

Main Results:

• Targeting TRalpha selectively is a key strategy due to its cardiac abundance.
• Significant research efforts have been invested in developing TR agonists.
• The development of selective ligands is still in its early stages, with limited chemical structures and no current TR ligands in clinical trials for metabolic diseases.

Conclusions:

• Selective TR agonists offer considerable therapeutic potential for metabolic diseases.
• The field of selective TR ligand development requires further advancement in chemical diversity and clinical validation.
• Despite extensive research, the clinical application of TR ligands for metabolic diseases remains a future prospect.